logo

For the Inventor, By the Inventor

Bronx, NY, United States of America

Qisheng Xin

This inventor holds 5 USPTO granted patents. Top assignee: Albert Einstein College of Medicine. Active years: 2016-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qisheng Xin. Retrieved from https://idiyas.com/inventor/qisheng-xin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 100.0

Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:

goldMedal5 out of 514 
 
Albert Einstein College of Medicine
 patents

Years Active: 2016-2023

Loading Chart...
5 patents (USPTO):Explore Patents
1. 11591324 - Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof (2023-02-28),
2. 10766886 - Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof (2020-09-08),
3. 10189827 - Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof (2019-01-29),
4. 9890143 - Retinoic acid receptor antagonists as chaperone-mediated authophagy modulators and uses thereof (2018-02-13),
5. 9512092 - Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof (2016-12-06),

Title: Qisheng Xin: Innovator in Chaperone-Mediated Autophagy

Introduction

Qisheng Xin is a prominent inventor based in Bronx, NY (US). He has made significant contributions to the field of biomedical research, particularly in the area of chaperone-mediated autophagy. With a total of 5 patents, his work focuses on innovative solutions to protect cells from various forms of stress.

Latest Patents

Among his latest patents, Qisheng Xin has developed compounds and methods that serve as retinoic acid receptor antagonists. These innovations are designed to selectively activate chaperone-mediated autophagy (CMA), which helps protect cells from oxidative stress, proteotoxicity, and lipotoxicity. His work aims to antagonize the activity of retinoic acid receptor alpha (RARα) in subjects who require such interventions.

Career Highlights

Qisheng Xin is affiliated with the Albert Einstein College of Medicine, where he continues to advance his research. His career is marked by a commitment to understanding and manipulating cellular processes to improve health outcomes.

Collaborations

He has collaborated with notable researchers in his field, including Ana Maria Cuervo and Evripidis Gavathiotis. These partnerships have further enriched his research and contributed to the advancement of knowledge in chaperone-mediated autophagy.

Conclusion

Qisheng Xin's innovative work in the realm of chaperone-mediated autophagy exemplifies the impact of dedicated research on cellular health. His contributions are paving the way for new therapeutic strategies in medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…